# Pulmokine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pulmokine

- Industry: Pharmaceuticals
- Headquarters: Rensselaer, US
- Website: www.pulmokine.net
- Total disclosed funding: $1M
- Latest round: Seed (Mar 3, 2015)
- Investors on record: 1

## About

Pulmokine is a company dedicated to developing innovative respiratory health solutions aimed at improving the quality of life for individuals suffering from breathing difficulties. Their focus is on enhancing lung function and breathability for better health outcomes.Founded in 2007 and headquartered in Rensselaer, US, Pulmokine specializes in respiratory health products. The company has completed 3 deals, with its most recent funding round being a Seed round of USD 1.00 mn from Broadview Ventures on March 3, 2015. Larry Zisman serves as the CEO.Pulmokine specializes in innovative respiratory health solutions designed to enhance the quality of life for individuals with breathing difficulties. Their primary product offerings include proprietary formulations that aim to alleviate respiratory conditions by improving lung function and easing breathability. These products target patients suffering from chronic respiratory diseases, such as asthma and COPD, as well as individuals seeking preventive measures for respiratory health. Pulmokine's solutions are developed with a focus on efficacy and user experience, ensuring they meet the needs of both healthcare professionals and end consumers. The company distributes its products across North America and Europe, expanding its reach to a diverse clientele that includes individual consumers, healthcare providers, and pharmacies.Pulmokine generates revenue through a direct-to-consumer model, offering its products through online platforms and retail partnerships. The company has established a pricing structure that allows for individual sales, as well as potential subscription models for ongoing customer engagement. Through these transactions, Pulmokine ensures a consistent supply of their flagship respiratory health products, designed to address specific health concerns. Each transaction facilitates ease of purchase for consumers and enables partnerships with healthcare facilities to enhance product accessibility. This approach fosters customer loyalty and positions Pulmokine within the competitive landscape of respiratory health solutions.Pulmokine is focused on designing and launching new respiratory health products in the upcoming period to expand its offerings. The company is also planning to enter new geographic markets, specifically targeting regions across Asia by the end of 2025. The recent Seed financing of USD 1.00 mn raised in March 2015 will support these initiatives, enabling the development and marketing of new products as well as the expansion into these new markets.

## Funding rounds

- Seed, Mar 3, 2015, $1M — Broadview Ventures

## Investors

- Broadview Ventures (https://capitalatlas.ai/funds/broadview-ventures) — Seed